A
Here are 3 key points from the VITAL-H study on testing three existing drugs for slowing aging:
1. Testing Existing Drugs for Human Aging
UT Health San Antonio is launching a $38 million clinical trial (VITAL-H) to test whether rapamycin, semaglutide, and dapagliflozin can slow biological aging in humans.
The trial focuses on adults aged 60–65 in relatively good health, measuring biological markers of aging and intrinsic capacity rather than lifespan.
Goal: increase healthspan—more years of healthy, independent living—rather than immortality.
2. Each Drug Has a Unique Mechanism
Rapamycin: Immune modulator with previous evidence of extending lifespan in mice.
Semaglutide: GLP-1 drug known for diabetes and weight loss; may benefit multiple age-related conditions.
Dapagliflozin: Diabetes drug that may reduce chronic inflammation (“inflammaging”), potentially slowing age-related decline.
The combination allows researchers to see if drugs already approved for other uses can impact aging processes in humans.
3. Inclusive, Human-Centered Approach
The study emphasizes diverse participant recruitment, especially the historically underrepresented Hispanic population in South Texas.
It uses continuous monitoring (Oura rings, check-ins) to capture detailed functional data.
This approach aims to move longevity science from hype to credible, applicable medicine, focusing on outcomes that matter for everyday life.
Tagline:
“Repurposing existing drugs to slow aging and extend healthy life.”
No comments:
Post a Comment